- Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact2010 | First Faculty of Medicine
- Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab2019 | First Faculty of Medicine
- Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab2014 | Faculty of Medicine in Hradec Králové
- Emerging glyco-based strategies to steer immune responses2021 | Faculty of Science
- Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma2017 | Publication without faculty affiliation
- A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA2020 | First Faculty of Medicine
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma2017 | First Faculty of Medicine